Ocriplasmin for diabetic retinopathy

Expert Opinion on Biological Therapy

Volumn 13, Issue 12, 2013, Pages 1741-1747

  De Smet, Marc D ^a,b   Castilla, Miguel ^a  

^a Centers for Specialized Ophthalmology   (Switzerland)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Diabetic vitreopathy; Hyaluronidase; Laser; Neovascularization; Ocriplasmin; Pharmacologic vitreolysis; Posterior vitreous detachment; Proliferative diabetic retinopathy

Indexed keywords

HYALURONIDASE; OCRIPLASMIN; PLASMIN;

ARTICLE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; EYE PROTECTION; HUMAN; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOPSIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA HOLE; RETINA NEOVASCULARIZATION; RISK REDUCTION; TREATMENT DURATION; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS BODY DETACHMENT; VITREOUS DISEASE; VITREOUS FLOATERS;

CLINICAL TRIALS AS TOPIC; DIABETIC RETINOPATHY; DRUG EVALUATION; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HUMANS; PEPTIDE FRAGMENTS;

EID: 84887878253     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.853737     Document Type: Article

References (51)

1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. New Engl J Med 2012;366:1227-39
2. Rema M, Premkumar S, Anitha B, et al. Prevalence of diabetic retinopathy in urban India: The Chennai Urban Rural Epidemiology Study (CURES) eye 3. Invest Ophthalmol Vis Sci 2005;46:2328-33
3. Hirsch IB, Brownlee M. Beyond hemogroblin A1c -need for additional markers of risk for diabetic microvascular complications. J Am Med Assoc 2010;303:2291-2
4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration. Arch Int Med 2009;169:1307-16
5. Happich M, Reitberger U, Breitscheidel L, et al. The economic burden of diabetic retinopathy in Germany in 2002. Graefes Arch Clin Exp Ophthalmol 2008;246:151-9
6. Gowda K, Zinnanti WJ, LaNoue KF. The influence of diabetes on glutamate metabolism in retinas. J Neurochem 2011;117:309-20
7. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005;57:173-85
8. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res 2013;34:19-35
9. Yoshida S, Nakama T, Ishikawa K, et al. Antiangiogenic shift in vitreous after vitrectomy in patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2012;53:6997-7003
10. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147-63
11. Stefánsson E, Machemer R, de Juan E Jr, et al. Retinal oxygenation and laser treatment in patients with diabetic retinopathy. Am J Ophthalmol 1992;113:36-8
12. Giblin FJ, Quiram PA, Leverenz VR, et al. Enzyme-induced posterior vitreous detachment in the rat produces increased lens nuclear pO2 levels. Exp Eye Res 2009;88:286-92
13. Holekamp NM, Shui YB, Beebe DC. Vitrectomy surgery increases oxygen exposure to the lens: A possible mechanism for nuclear cataract formation. Am J Ophthalmol 2005;139:302-10
14. Blankenship GW, Machemer R. Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology 1985;92:503-6
15. de Smet M, Gad El Kareem A, Zwinderman AH. The vitreous, the retinal interface in ocular health and disease. Ophthalmologica 2013; In press
16. Sebag J. Diabetic vitreopathy. Ophthalmology 1999;103:323-8
17. Sebag J. Anomalous posterior vitreous detachment: A unifying concept in vitreo-retinal disease. Graefe's Arch Clin Exp Ophthalmol 2004;242:690-8
18. Blankenship GW, Machemer R. Prophylactic vitrectomy in proliferative diabetic retinopathy. Mod Probl Ophthalmol 1977;18:236-41
19. Johnson MW. Posterior vitreous detachment: Evolution and complications of its early stages. Am J Ophthalmol 2010;149:371-82
20. Uemura A, Nakamura M, Kachi S, et al. Effect of Plasmin on Laminin and Fibronectin During Plasmin-Assisted Vitrectomy. Arch Ophthalmol 2005;123:209-13
21. Sebag J. Classifying posterior vitreous detachment: A new way to look at the invisible. Br J Ophthalmol 1997;81:521
22. Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: A review. Clin Ophthalmol 2011;5:1151-65
23. Gad El Kareem AM, Willikens B, Stassen JM, et al. Differential vitreous dye diffusion following microplasmin or plasmin pre-treatment. Curr Eye Res 2010;35:235-41
24. Chen WL, Mo W, Sun K, et al. Microplasmin degrades fibronectin and laminin at vitreoretinal interface and outer retina during enzymatic vitrectomy. Curr Eye Res 2009;34(12):1057-64
25. de Smet MD, Valmaggia C, Zarrantz J, et al. Microplasmin: Ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci 2009;50:814-19
26. Gad El Kareem A, Willikens B, Vanhove M, et al. Characterization of a stabilized form of microplasmin for the induction of a posterior vitreous detachment. Curr Eye Res 2010;35:909-15
27. de Smet MD, Jonckx B, Vanhove M, et al. Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 2012;53:8208-13
28. Aerts F, Noppen B, Fonteyn L, et al. Mechanism of inactivation of ocriplasmin in porcine vitreous. Biophys Chem 2012;165-166:30-8
29. Sebag J, Ansari R, Suh K. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefe's Arch Clin Exp Ophthalmol 2007;245(4):576-80
30. Gad Elkareem AM, de Smet MD. Effect of microplasmin on the clearance of vitreous hemorrhage from an experimental model in rabbits. Acta Ophthalmol 2012; In press
31. Stalmans P, de Laey C, de Smet M, et al. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: Results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina 2010;30:1122-7
32. de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: The MIVI I trial. Ophthalmology 2009;116:1349-55
33. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. New Engl J Med 2012;367:606-15
34. Benz MS, Packo KH, Gonzalez V, et al. A Placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology 2010;117:791-7
35. Sebag J, Nie S, Reiser K, et al. Raman spectroscopy of human vitreous in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1994;35:2976-80
36. Elbendary AM, Elwan MM, Azzam HA, et al. Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction. Curr Eye Res 2011;36:534-9
37. Diaz-Llopis M, Udaondo P, Arevalo F, et al. Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther 2009;25:379-84
38. Sebag J. Pharmacologic vitreolysis -premise and promise of the first decade. Retina 2007;29:871-4
39. DeCroos FC, Toth CA, Folgar FA, et al. Characterization of vitreoretinal interface disorders using OCT in the interventional Phase III trials of ocriplasmin. Invest Ophthalmol Vis Sci 2012;53:6504-11
40. Elsawy MF. Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema. Clin Ophthalmol 2012;6:2063-8
41. Stitt AW, Lois N, Medina RJ, et al. Advances in our understanding of diabetic retinopathy. Clin Sci (Lond) 2013;125:1-17
42. Aboutable T, Kalvodova B. Vitrectomy for diabetic cystoid macular edema -Results of 72 cases. Klin Monatsbl Augenheilkd 2005;222:643-8
43. Diabetic Retinopathy Clinical Research Network Writing Committee on behalf of the DRCR.net. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010;117:1087-93
44. Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249:15-27
45. Wang ZLM, Zhang XM, Xu XM, et al. PVD following plasmin but not hyaluronidase: Implications for combination pharmacologic vitreolysis therapy. Retina 2005;25:38-43
46. Stalmans P, de Laey C, de Smet M, et al. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: Results of a prospective, randomized, shamcontrolled phase II trial (the MIVI-IIT trial). Retina 2010;30:1122-7
47. de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: The MIVI I trial. Ophthalmol 2009;116:1349-55
48. Wong TY, Mwamburi M, Klein R, et al. Rates of progression in diabetic retinopathy during different time periods. Diabetes Care 2009;32:2307-13
49. Harris Nwanyanwu K, Talwar N, Gardner TW, et al. Predicting development of proliferative diabetic retinopathy. Diabetes Care 2013;36:1562-8 10.2337/dc12-0790
50. Roy M, Klein R, Janal M. Retinal venular diameter as an early indicator of progression to proliferative diabetic retinopathy with and without high-risk characteristics in African Americans with type I diabetes mellitus. Arch Ophthalmol 2011;129:8-15
51. Valsania P, Warram JH, Rand L, et al. Different determinants of neovascularization on the optic disc and on the retina in patients with severe nonproliferative diabetic retinopathy. Arch Ophthalmol 1993;111:202-6